Navigation Links
The fight against uterine fibroid tumors
Date:4/27/2010

CHICAGO ---As many as 75 percent of women have uterine fibroids (leiomyomas), and approximately one-third to one-half of those women become symptomatic at some point during their reproductive lives experiencing irregular uterine bleeding, anemia, pelvic pain or recurrent pregnancy loss.

"Uterine fibroids represent the most prevalent benign gynecologic problem in our nation. This is truly an understudied area and a serious public health problem," said Serdar E. Bulun, M.D., George H. Gardner professor of clinical gynecology and chief of the division of reproductive biology research at Northwestern University Feinberg School of Medicine, who also is a physician at Northwestern Memorial Hospital.

Thanks to $5.7 million in funding from the Eunice Kennedy Shriver National Institute of Child Health and Development, part of the National Institutes of Health, Bulun and researchers at the Uterine Leiomyoma Research Center at Feinberg have the funding they need to continue investigating new treatments of uterine fibroids.

Principal investigator of the center grant, Bulun is studying the cause of this chronic problem, as well as treatment options such as investigating hormonal pathways and defining molecular targets for existing or upcoming pharmaceutical compounds developing novel and alternative management options.

Bulun's research suggests that the hormone progesterone, which enables and activates fibroid growth during childbearing years, stimulates uterine fibroids. His recent work uncovered the mechanism as to how a class of drugs called selective progesterone receptor modulators reduces fibroid size and associated symptoms. The mechanisms regulating the development and growth of these tumors are still not well understood, however, so treatment options for fibroids are limited.

Besides Bulun, Julie Kim, Debu Chakravarti, Takeshi Kurita, and Erica Marsh, M.D., from Feinberg and Romana Nowak, from University of Illinois at Urbana-Champaign, lead key projects at the Uterine Leiomyoma Research Center.

Uterine fibroids are typically treated surgically, through a myomectomy or hysterectomy, or using newer technologies involving interventional radiology or high-intensity ultrasound. GnRH agonists, developed in the 1980s, are the only class of drugs available to treat fibroids, but their success is extremely limited, and side effects prevent long-term use of the medication.

The renewable five-year P01 Program Project offers Bulun and his colleagues the opportunity to find answers to these uncertainties and diminish the suffering caused by uterine fibroids.

"This center is a unique entity," Bulun said. "We approach the translational aspects of uterine fibroids in a multidisciplinary manner. We hope our research will encourage the pharmaceutical industry and clinicians to set up clinical trials."


'/>"/>

Contact: Erin White
ewhite@northwestern.edu
847-491-4888
Northwestern University
Source:Eurekalert

Related biology news :

1. Clemson chemists discover new way antioxidants fight debilitating diseases
2. Social habits of cells may hold key to fighting diseases
3. Advance in effort to fight malaria by tricking the mosquitos sense of smell
4. Yale scientists use nanotechnology to fight E. coli
5. Researchers develop liquid crystal pharmaceuticals to fight cancer and other diseases
6. Japanese beetle may help fight hemlock-killing insect
7. When it comes fighting to C. difficile, the Palme dOr goes to soap and warm water
8. Fighting the spread of food poisoning
9. Gold nanorods shed light on new approach to fighting cancer
10. UMass Medical School researchers receive $8.5M grant award to fight AIDS
11. UV light improving chances of fighting cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/10/2016)... , March 10, 2016   Unisys Corporation (NYSE: ... Border Protection (CBP) is testing its biometric identity solution ... Diego to help identify certain non-U.S. citizens leaving ... The test, designed to help determine the efficiency and accuracy ... in February and will run until May 2016. --> ...
(Date:3/9/2016)... Germany , March 9, 2016 ... country,s government identified that more than 23,000 public service ... or had been receiving their salary unlawfully.    ... African country,s government identified that more than 23,000 public ... name or had been receiving their salary unlawfully.    ...
(Date:3/8/2016)...   Valencell , the leading innovator in ... secured $11M in Series D financing. The investment ... fund being launched by UAE-based financial services company ... TDF Ventures and WSJ Joshua Fund. Valencell plans ... growth and accelerate its pioneering innovation in accurate ...
Breaking Biology News(10 mins):
(Date:5/25/2016)... ... May 25, 2016 , ... WEDI, the nation’s leading ... today announced that Charles W. Stellar has been named by the WEDI Board of ... January 2016. As an executive leader with more than 35 years of experience in ...
(Date:5/24/2016)... ... May 24, 2016 , ... Last week, Callan Capital, an integrated ... entrepreneurs, held The Future of San Diego Life Science event at the Estancia La ... community attended the event with speakers Dr. Rich Heyman, former CEO of Aragon and ...
(Date:5/23/2016)... 2016 Oxitec CEO Hadyn Parry ... 10:15 a.m. ET before the United States House Committee on ... can play in controlling the spread of the Aedes ...      (Logo: http://photos.prnewswire.com/prnh/20150630/227348 ) ... self-limiting gene. Trials in Brazil , ...
(Date:5/20/2016)... CA (PRWEB) , ... May 20, 2016 , ... The ... 10 of its most experienced veterinary clients have treated over 100 of their own ... edge technology to provide the highest level of care for their patients. , ...
Breaking Biology Technology: